BAY-218 NEW
| Price | $34 | $46 | $66 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: BAY-218 | CAS No.: 2162982-11-6 |
| Purity: 99.85% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | BAY-218 |
| Description | Bindarit (AF2838)is an aryl hydrocarbon receptor (AHR) antagonist with IC50 of 39.9 nM in the human glioblastoma U87 cell line. BAY-218 inhibition of AhR stimulates pro-inflammatory monocyte and T cell responses in vitro and drives anti-tumor immune responses, leading to reduced tumor growth in vivo. |
| In vitro | METHODS: Human monocytic U937 cells were treated with BAY-218 (AHR antagonist 1)(1 nM, 3nM, 10nM, 30nM, 100nM, 300nM, 1 μΜ and 3μΜ) and the IC50 values ??were determined. RESULTS BAY-218 exhibited CYP1A1 inhibitory activity with an IC50 of 70.7 μM in the human monocytic U937 cell line. [1] METHODS: BAY-218 (72 pM, 0.25 nM, 0.89 nM; 3.1 nM, 1 1 nM, 38 nM, 130 nM, 470 nM, 1.6 pM, 5.7 p, 20 μM) was used to treat U87 glioblastoma cells endogenously expressing AHR and the IC50 value was determined. RESULTS BAY-218 could inhibit the activity of AHR in U87 glioblastoma cells with an IC50 of 39.9 μM. [1] |
| In vivo | METHODS: Bindarit (AF2838)(30 mg/kg, oral, twice daily) and aPD-L1 (10 mg/kg, intraperitoneal injection, twice daily) were used to treat mice with CT26 tumor cell xenografts injected subcutaneously in the flank to observe their anti-tumor ability. RESULTS Combination therapy of BAY-218 and aPD-L1 inhibited tumor growth in mice. [1] |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 250 mg/mL (622.17 mM) |
| Keywords | cancer | human monocytic U937 cells | AHR antagonist1 | inhibit | BAY-218 | Aryl Hydrocarbon Receptor | Inhibitor | BAY 218 | aryl hydrocarbon receptor (AHR) | U87 glioblastoma cells | AHR antagonist-1 | immune | BAY218 | AhR |
| Inhibitors Related | Nimodipine | Carbidopa monohydrate | Diosmin | (-)-Perillaldehyde | Prochloraz | Benzyl butyl phthalate | Skatole | L-Kynurenine | Indole-3-carbinol | MeBIO | Leflunomide | Mexiletine hydrochloride |
| Related Compound Libraries | Nonsteroidal Anti-Inflammatory Compound Library | Nuclear Receptor Compound Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $82.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $17.00/1g |
VIP5Y
|
Career Henan Chemica Co
|
2020-10-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY